<DOC>
	<DOCNO>NCT01627990</DOCNO>
	<brief_summary>The purpose study observe tolerability , safety efficacy preventative treatment use Nivestim™ patient receive cytotoxic chemotherapy cancer .</brief_summary>
	<brief_title>Nivestim™ Treatment Malignant Diseases</brief_title>
	<detailed_description>This non-interventional , descriptive , national , multi-site , longitudinal prospective observational study in-patients adult minor undergo cytotoxic chemotherapy , treat prophylactically Nivestim™ order reduce duration neutropenia reduce incidence chemotherapy-induced Febrile neutropenia ( FN ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>No age limit Declaration inform consent sign patient legal guardian Patients solid tumour malignant haematological tumour Patients cytotoxic chemotherapy plan , irrespective cycle Patients due undergo , undergo , ( primary secondary ) prophylactic treatment use Nivestim™ , either shorten duration neutropenia prevent occurrence chemotherapy induce febrile neutropenia ( FN ) . Patients chronic myeloid leukaemia ( CML ) myelodysplastic Syndrome ( MDS ) Patients hypersensitive active substance one excipients Nivestim™ Patients undergoing chemotherapy Patients treat curatively GranulocyteColony Stimulating Factor ( GCSF )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cytotoxic chemotherapy</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>Malignant haematological tumour</keyword>
</DOC>